表紙:遺伝子編集市場の2030年までの予測:製品別、技術別、用途別、エンドユーザー別、地域別の世界分析
市場調査レポート
商品コード
1383399

遺伝子編集市場の2030年までの予測:製品別、技術別、用途別、エンドユーザー別、地域別の世界分析

Gene Editing Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and By Geography

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
遺伝子編集市場の2030年までの予測:製品別、技術別、用途別、エンドユーザー別、地域別の世界分析
出版日: 2023年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界の遺伝子編集市場は2023年に74億5,000万米ドルを占め、予測期間中にCAGR 17.5%で成長し、2030年には230億5,000万米ドルに達すると予測されています。

遺伝子編集」として知られる技術群により、研究者は生物のDNAを改変することができます。これらの技術により、ゲノム内の特定の場所で遺伝物質を変更、追加、除去することが可能になります。ゲノム編集は、ヒトにおける病気の予防と治療の両方にとって魅力的な分野です。がん、心臓病、精神疾患、HIV感染症など、より複雑な疾患も、これを用いることで治療や予防が可能になる可能性があります。

米国立衛生研究所(NIH)によると、2,500万人から3,000万人のアメリカ人が罹患している希少疾患はおよそ7,000あるといわれています。

高まるゲノミクスの応用

ゲノミクスは、食品の品質と安全性の検査にますます利用されるようになっています。ゲノムを編集する技術は、新薬の発見にも、ヒトの遺伝性疾患の特定と治療にも不可欠です。NGS、DNA分析とプロファイリング、動植物の遺伝子工学はすべてゲノム編集を採用しています。魚類の個体群を評価する場合、NGSは魚類の卵や幼生を識別するためのDNAバーコーディングや、魚類群集を完全に特徴付けるために利用することができます。したがって、予測期間中は、ゲノム解析の応用分野が拡大するため、ゲノム編集技術に対する需要が増加する可能性が高いです。

高コスト

遺伝子編集療法の研究開発にはコストと時間がかかります。企業や組織が綿密な事前試験や臨床試験に必要な資金を調達するのは難しい可能性があります。遺伝子編集医療の開発は臨床試験に大きく依存しており、それにはかなりの費用がかかります。遺伝子編集療法の安全性と有効性を示すためには、通常、いくつかの段階と多数の人々を含むこれらの試験が必要です。したがって、高いコストは市場拡大の大きな障壁となっています。

遺伝性疾患の有病率の上昇

遺伝子編集市場に拍車をかけている主な要因の1つは、遺伝性疾患の有病率の上昇です。珍しい病気やさまざまな遺伝性疾患の診断を受ける人の増加が、本質的にこの動向を特徴づけています。CRISPR-Cas9のような遺伝子編集技術には、これらの病気の原因となっている根本的な遺伝子異常を特定し修正する能力があるため、患者は最終的に希望を持つことができます。こうした要因が市場の需要を後押ししています。

CRISPRの標的外影響

遺伝子編集技術の重大な制約は、CRISPR技術の標的外影響です。CRISPR-Cas9は驚異的な精度で特定の遺伝子を標的とすることができるが、意図した標的以外の場所で意図しない改変を引き起こす可能性もあります。CRISPR技術の応用は、このオフ対象活性の結果としてリスクや困難をもたらす可能性があります。これらの要因が市場拡大の妨げとなっています。

COVID-19の影響

パンデミックによって遺伝子編集産業が恩恵を受けたのは、社会的距離感規範と病院のベッド不足によって、在宅患者ケアシステムが最大限に適応せざるを得なかったからです。COVID-19の大流行はわれわれの生活を一変させました。また、科学界における創造と協力への傾倒をさらに加速させました。パンデミックが世界中に広がる中、科学者たちは治療法、予防接種、診断法の開発に熱中しています。COVID-19の原因となる新型コロナウイルスSARS-CoV-2に取り組むため、科学者たちはハイスループット実験自動化、人工知能、機械学習に注目しています。SARS-CoV-2は感染した患者を隔離し、適切な医療対応を観察するために必要です。このように遺伝子編集市場はCOVID-19の流行から恩恵を受けた。

予測期間中、試薬・消耗品セグメントが最大になる見込み

試薬・消耗品セグメントは最大のシェアを占めると推定されます。試薬・消耗品には、フォイルシール、スライドホルダー、プレート、チップ、チューブストリップ、ライブラリー調製、精製、対象濃縮キットなど幅広いアイテムが含まれます。消耗品市場は、ゲノミクスの様々な産業への応用が拡大した結果、上昇すると予測されています。エピジェネティクスやトランスクリプトミクスにおけるNGSの活用も、ライブラリー調製技術の発展によって可能になっています。対象シーケンスや全ゲノムシーケンスなどのシーケンス用途では、これらのキットが使用されています。

予測期間中、クラスター化規則的間隔ショートパリンドロームリピートセグメントが最も高いCAGRが見込まれる

クラスター化された等間隔短パリンドローム反復配列セグメントは、予測期間中に有利な成長を遂げると予測されています。従来の遺伝子改変法に代わるものとして、CRISPR-クラスター化規則的間隔短縮回文反復は遺伝子編集に不可欠なツールとなっています。Cas9酵素がCRISPRを従来のDNA編集とは一線を画すものにしています。CRISPRは、損傷したDNA配列や望ましくないDNA配列を除去することで、遺伝子を再編成し、残りのDNAが新たな構成をとることができるようにします。

最もシェアの高い地域

推定期間中、北米が最大の市場シェアを占めました。遺伝子編集の最も重要な地域市場は北米です。米国はこの地域の主な収益源となっています。米国では、ベンチャーキャピタル、政府機関、非公開会社が遺伝子編集分野で多額の資金と投資を行っています。遺伝子編集技術の研究開発と商業化は、こうした資金調達によって加速されてきました。治療的介入の開発と遺伝子編集事業の拡大は、資金調達の可能性によって可能となっています。

CAGRが最も高い地域:

アジア太平洋は、予測期間中に収益性の高い成長を示すと予想されます。この背景には、技術的ブレークスルーの増加、新興地域におけるバイオテクノロジー産業の隆盛、がんやその他の遺伝子異常の有病率の上昇があります。CRISPR技術の革新は、日本ではまだ著しく成長しています。一方、インドでは新たなCRISPR研究が市場成長を促進すると予想されています。さらに、インドの研究者は、広く使われているCRISPR-Cas9遺伝子編集法の異なるバリエーションを開発しました。この変種は、意図しないDNA変化を引き起こすことなく遺伝子編集の精度を高める可能性があります。したがって、今後数年間は、これらの変数がアジア太平洋の遺伝子編集市場に影響を及ぼすと予想されます。

無料のカスタマイズ提供

本レポートのすべての顧客は、以下の無料カスタマイズオプションのいずれかを受けることができる:

  • 企業プロファイル
    • 追加市場参入企業の包括的プロファイリング(3社まで)
    • 主要企業のSWOT分析(3社まで)
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推定・予測・CAGR(注:フィージビリティチェックによる)
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データ鉱業
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査ソース
    • 前提条件

第3章 市場動向分析

イントロダクション

促進要因

抑制要因

機会

脅威

製品分析

技術分析

用途分析

エンドユーザー分析

新興市場

新型コロナウイルス感染症(COVID-19)の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界の遺伝子編集市場:製品別

  • イントロダクション
  • ソフトウェアとシステム
  • サービス
  • 試薬・消耗品

第6章 世界の遺伝子編集市場:技術別

  • イントロダクション
  • 転写活性化因子様エフェクターヌクレアーゼ
  • アンチセンス
  • クラスター化された規則的に間隔をあけられた短い回文反復(CRISPR)
  • ジンクフィンガーヌクレアーゼ(ZFN)
  • その他の技術

第7章 世界の遺伝子編集市場:用途別

  • イントロダクション
  • 遺伝子工学
  • 細胞株工学
  • 創薬と開発
  • その他の用途

第8章 世界の遺伝子編集市場:エンドユーザー別

  • イントロダクション
  • 学術研究機関
  • 製薬会社およびバイオテクノロジー企業
  • その他のエンドユーザー

第9章 世界の遺伝子編集市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他のアジア太平洋
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他の南米
  • 中東およびアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他の中東およびアフリカ

第10章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第11章 企業プロファイル

  • Sangamo Therapeutics, Inc.
  • Beam Therapeutics
  • Integrated DNA Technologies, Inc.
  • Thermo Fisher Scientific
  • Horizon Discovery Ltd.
  • Precision Biosciences
  • CRISPR Therapeutics
  • GeneScript
  • Agilent Technologies
  • Intellia Therapeutics, Inc.
  • Caribou Biosciences, Inc.
  • Lonza
  • Perkinelmer
  • Editas Medicine
  • Tecan Life Sciences
  • Amsbio
  • Creative Biogene
図表

List of Tables

  • Table 1 Global Gene Editing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Gene Editing Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
  • Table 4 Global Gene Editing Market Outlook, By Services (2021-2030) ($MN)
  • Table 5 Global Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 6 Global Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 7 Global Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
  • Table 8 Global Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
  • Table 9 Global Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
  • Table 10 Global Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
  • Table 11 Global Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 12 Global Gene Editing Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
  • Table 14 Global Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
  • Table 15 Global Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 16 Global Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 17 Global Gene Editing Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 19 Global Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 20 Global Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 21 North America Gene Editing Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Gene Editing Market Outlook, By Product (2021-2030) ($MN)
  • Table 23 North America Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
  • Table 24 North America Gene Editing Market Outlook, By Services (2021-2030) ($MN)
  • Table 25 North America Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 26 North America Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 27 North America Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
  • Table 28 North America Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
  • Table 29 North America Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
  • Table 30 North America Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
  • Table 31 North America Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 32 North America Gene Editing Market Outlook, By Application (2021-2030) ($MN)
  • Table 33 North America Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
  • Table 34 North America Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
  • Table 35 North America Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 36 North America Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 37 North America Gene Editing Market Outlook, By End User (2021-2030) ($MN)
  • Table 38 North America Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 39 North America Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 40 North America Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 41 Europe Gene Editing Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Gene Editing Market Outlook, By Product (2021-2030) ($MN)
  • Table 43 Europe Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
  • Table 44 Europe Gene Editing Market Outlook, By Services (2021-2030) ($MN)
  • Table 45 Europe Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 46 Europe Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 47 Europe Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
  • Table 48 Europe Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
  • Table 49 Europe Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
  • Table 50 Europe Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
  • Table 51 Europe Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 52 Europe Gene Editing Market Outlook, By Application (2021-2030) ($MN)
  • Table 53 Europe Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
  • Table 54 Europe Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
  • Table 55 Europe Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 56 Europe Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 57 Europe Gene Editing Market Outlook, By End User (2021-2030) ($MN)
  • Table 58 Europe Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 59 Europe Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 60 Europe Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 Asia Pacific Gene Editing Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Gene Editing Market Outlook, By Product (2021-2030) ($MN)
  • Table 63 Asia Pacific Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
  • Table 64 Asia Pacific Gene Editing Market Outlook, By Services (2021-2030) ($MN)
  • Table 65 Asia Pacific Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 66 Asia Pacific Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 67 Asia Pacific Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
  • Table 68 Asia Pacific Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
  • Table 69 Asia Pacific Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
  • Table 70 Asia Pacific Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
  • Table 71 Asia Pacific Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 72 Asia Pacific Gene Editing Market Outlook, By Application (2021-2030) ($MN)
  • Table 73 Asia Pacific Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
  • Table 74 Asia Pacific Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
  • Table 75 Asia Pacific Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 76 Asia Pacific Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 77 Asia Pacific Gene Editing Market Outlook, By End User (2021-2030) ($MN)
  • Table 78 Asia Pacific Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 79 Asia Pacific Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 80 Asia Pacific Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 South America Gene Editing Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Gene Editing Market Outlook, By Product (2021-2030) ($MN)
  • Table 83 South America Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
  • Table 84 South America Gene Editing Market Outlook, By Services (2021-2030) ($MN)
  • Table 85 South America Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 86 South America Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 87 South America Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
  • Table 88 South America Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
  • Table 89 South America Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
  • Table 90 South America Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
  • Table 91 South America Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 92 South America Gene Editing Market Outlook, By Application (2021-2030) ($MN)
  • Table 93 South America Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
  • Table 94 South America Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
  • Table 95 South America Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 96 South America Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 97 South America Gene Editing Market Outlook, By End User (2021-2030) ($MN)
  • Table 98 South America Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 99 South America Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 100 South America Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 Middle East & Africa Gene Editing Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Gene Editing Market Outlook, By Product (2021-2030) ($MN)
  • Table 103 Middle East & Africa Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
  • Table 104 Middle East & Africa Gene Editing Market Outlook, By Services (2021-2030) ($MN)
  • Table 105 Middle East & Africa Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 106 Middle East & Africa Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 107 Middle East & Africa Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
  • Table 108 Middle East & Africa Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
  • Table 109 Middle East & Africa Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
  • Table 110 Middle East & Africa Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
  • Table 111 Middle East & Africa Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 112 Middle East & Africa Gene Editing Market Outlook, By Application (2021-2030) ($MN)
  • Table 113 Middle East & Africa Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
  • Table 114 Middle East & Africa Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
  • Table 115 Middle East & Africa Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 116 Middle East & Africa Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 117 Middle East & Africa Gene Editing Market Outlook, By End User (2021-2030) ($MN)
  • Table 118 Middle East & Africa Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 119 Middle East & Africa Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 120 Middle East & Africa Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
目次
Product Code: SMRC24249

According to Stratistics MRC, the Global Gene Editing Market is accounted for $7.45 billion in 2023 and is expected to reach $23.05 billion by 2030 growing at a CAGR of 17.5% during the forecast period. A group of technologies known as "gene editing" enables researchers to modify an organism's DNA. These technologies make it possible to change, add, or remove genetic material at particular locations within the genome. Genome editing is a fascinating field for both illness prevention and treatment in humans. More complicated conditions like cancer, heart disease, mental illness, and HIV infection may also be treated and prevented by using it.

According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans.

Market Dynamics:

Driver:

Rising applications of genomics

Genomics is increasingly being used in food quality and safety testing. Technologies for editing genomes are essential for both finding new drugs and identifying and treating genetic diseases in humans. NGS, DNA analysis and profiling, and genetic engineering of plants and animals all employ genome editing. When evaluating fish populations, NGS can be utilized for DNA barcoding to identify fish eggs and larvae as well as to fully characterize fish communities. Therefore, during the projection period, there will likely be a rise in demand for genome editing technologies due to the expanding application areas of genomics.

Restraint:

High cost

Gene editing therapy research and development can be costly and time-consuming. It could be difficult for businesses and organizations to get the financing needed for in-depth pre- and clinical testing. The development of gene editing medicine heavily relies on clinical studies, which are quite expensive. These trials, which usually involve several phases and a large number of people, are required to show the safety and effectiveness of gene editing therapy. Therefore, high costs are a significant barrier to market expansion.

Opportunity:

Rising prevalence of genetic illnesses

One major factor fueling the gene editing market is the increase in the prevalence of genetic illnesses. An increase in the number of people receiving diagnoses for uncommon diseases and different genetic disorders essentially characterizes this trend. Patients may finally have hope due to gene editing technologies like CRISPR-Cas9, which have the ability to identify and fix the underlying genetic abnormalities causing these illnesses. These factors propel market demand.

Threat:

Off-target impacts of CRISPR

A significant constraint of gene editing technology is the off-target impacts of CRISPR technology. Although CRISPR-Cas9 can target certain genes with astonishing precision, it can also cause unintentional alterations at places other than the intended target. The application of CRISPR technology may present risks and difficulties as a result of this off-target activity. These factors hinder market expansion.

COVID-19 Impact

The industry for gene editing benefited from the pandemic because social distancing norms and a shortage of hospital beds forced home-based patient care systems to adapt to the fullest. The COVID-19 pandemic has changed our lives. It has also intensified the already swift inclinations toward creation and cooperation among the scientific community. With the pandemic spreading across the globe, scientists are working feverishly to develop treatments, vaccinations, and diagnoses. To tackle SARS-CoV-2, the new coronavirus that causes COVID-19, scientists are looking into high-throughput experimental automation, artificial intelligence, and machine learning. The SARS-CoV-2 is necessary for isolating infected patients and observing appropriate medical responses. Thus, the market for gene editing benefited from the COVID-19 epidemic.

The reagents & consumables segment is expected to be the largest during the forecast period

The reagents & consumables segment is estimated to hold the largest share. Reagents and consumables encompass a wide range of items, including foil seals, slide holders, plates, chips, tube strips, library preparation, purification, and target enrichment kits. The market for consumables is predicted to rise as a result of genomics' expanding applicability in a variety of industries. Utilizing NGS in epigenetic and transcriptomics has also been made possible by developments in library preparation technology. Applications for sequencing, including targeted and whole-genome sequencing, employ these kits.

The clustered regularly interspaced short palindromic repeats segment is expected to have the highest CAGR during the forecast period

The clustered regularly interspaced short palindromic repeats segment is anticipated to have lucrative growth during the forecast period. As an alternative to conventional genetic alteration methods, CRISPR-Clustered Regularly Interspaced Short Palindromic Repeats have become an essential tool for gene editing. The Cas9 enzymes set CRISPR apart from previous types of DNA editing. By removing damaged or undesirable DNA sequences, CRISPR reorganizes genes so that the remaining DNA can take on new configurations.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The most significant regional market for gene editing is North America. The US has become this region's main source of revenue. In the US, venture capitalists, governmental organizations, and private companies have made large financial and investment contributions in the gene editing field. Research and development, as well as the commercialization of gene editing technologies, have been accelerated by this financing. The development of therapeutic interventions and the expansion of gene editing businesses have been made possible by the availability of funding.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. This is due to increasing technological breakthroughs, a thriving biotechnology industry in emerging regions, and the rising prevalence of cancer and other genetic abnormalities. Innovation in CRISPR technology is still growing significantly in Japan. On the other hand, new CRISPR research is anticipated to propel market growth in India. Additionally, researchers in the nation developed a distinct variation of the widely used CRISPR-Cas9 gene-editing method. The variant may increase the accuracy of gene editing without causing unintended DNA changes. Therefore, in the upcoming years, it is anticipated that these variables will have an effect on the Asia-Pacific gene editing market.

Key players in the market

Some of the key players in the Gene Editing Market include: Sangamo Therapeutics, Inc., Beam Therapeutics, Integrated DNA Technologies, Inc., Thermo Fisher Scientific, Horizon Discovery Ltd., Precision Biosciences, CRISPR Therapeutics, GeneScript, Agilent Technologies, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Lonza, Perkinelmer, Editas, edicine, Tecan Life Sciences, Amsbio and Creative Biogene.

Key Developments:

In November 2022, Thermo Fisher Scientific (US) announced the launch of Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution suitable for commercial and clinical applications associated with AAV-based gene therapies.

In June 2022, Lonza (Switzerland) and Adva entered into a license agreement that will allow Adva to develop innovative solutions for the cell and gene therapies industry.

In February 2023, Gen Script (China) announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company's advanced gene-synthesis capability and enables Gen Script to provide the service levels required for novel vaccine and therapeutic development in life sciences.

Products Covered:

  • Software & Systems
  • Services
  • Reagents & Consumables

Technologies Covered:

  • Transcription Activator-Like Effector Nuclease
  • Antisense
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • Zinc Finger Nuclease (ZFN)
  • Other Technologies

Applications Covered:

  • Genetic Engineering
  • Cell Line Engineering
  • Drug Discovery & Development
  • Other Applications

End Users Covered:

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Product Analysis

3.7 Technology Analysis

3.8 Application Analysis

3.9 End User Analysis

3.10 Emerging Markets

3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gene Editing Market, By Product

  • 5.1 Introduction
  • 5.2 Software & Systems
  • 5.3 Services
  • 5.4 Reagents & Consumables

6 Global Gene Editing Market, By Technology

  • 6.1 Introduction
  • 6.2 Transcription Activator-Like Effector Nuclease
  • 6.3 Antisense
  • 6.4 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • 6.5 Zinc Finger Nuclease (ZFN)
  • 6.6 Other Technologies

7 Global Gene Editing Market, By Application

  • 7.1 Introduction
  • 7.2 Genetic Engineering
  • 7.3 Cell Line Engineering
  • 7.4 Drug Discovery & Development
  • 7.5 Other Applications

8 Global Gene Editing Market, By End User

  • 8.1 Introduction
  • 8.2 Academic and Research Institutes
  • 8.3 Pharmaceutical and Biotechnology Companies
  • 8.4 Other End Users

9 Global Gene Editing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Sangamo Therapeutics, Inc.
  • 11.2 Beam Therapeutics
  • 11.3 Integrated DNA Technologies, Inc.
  • 11.4 Thermo Fisher Scientific
  • 11.5 Horizon Discovery Ltd.
  • 11.6 Precision Biosciences
  • 11.7 CRISPR Therapeutics
  • 11.8 GeneScript
  • 11.9 Agilent Technologies
  • 11.10 Intellia Therapeutics, Inc.
  • 11.11 Caribou Biosciences, Inc.
  • 11.12 Lonza
  • 11.13 Perkinelmer
  • 11.14 Editas Medicine
  • 11.15 Tecan Life Sciences
  • 11.16 Amsbio
  • 11.17 Creative Biogene